Short term safety of thoracoscopic talc pleurodesis for recurrent primary spontaneous pneumothorax. A prospective European multicenter study.

Authors: Pierre-Olivier Bridevaux1-2, Jean-Marie Tschopp1, Giuseppe Cardillo3, Charles-Hugo Marquette4, Marc Noppen5, Philippe Astoul6, Peter Driesen7, Chris T Bolliger8, Marios E Froudarakis9, Julius P Janssen10

Institutions: 1Centre Valaisan de Pneumologie Montana CH, 2Division of Pulmonary Medicine, University Hospitals of Geneva, Geneva, Switzerland 3Azienda Ospedaliera San Camillo Forlanini, Carlo Forlanini Hospital Rome I, 4University Hospital Nice, F 5University Hospital Brussels B, 6Hôpital Ste Marguerite Marseille F, 7Algemeen Ziekenhuis Turnhout B, 8Tygerberg Academic Hospital Cape Town SA 9University Hospital Alexandroupoli GR, 10Canisius Wilhelmina Hospital Nijmegen NL.

Disclaimer: none

Corresponding author: Pierre-Olivier Bridevaux
1211 Geneva, Switzerland Phone: +41 223729895 Fax: +41 223729909
Email: pierre-olivier.bridevaux@hcuge.ch

Word Count: Text: (not including title) 1246 Abstract: 199

Tables: 2 Figures: 3

Key words: Pleural disease, pneumothorax, talc pleurodesis, thoracoscopy
ABSTRACT

Background

Safety of talc pleurodesis is disputed following reports of talc induced acute respiratory distress syndrome (ARDS) and death. We investigated the safety of large-particle talc for thoracoscopic pleurodesis to prevent recurrence of primary spontaneous pneumothorax (PSP).

Method

Patients (n=418) with recurrent PSP were enrolled between 2002 and 2008 in 9 centres in Europe and South Africa. Main exclusion criteria were infection, heart disease, coagulation disorders. Serious adverse events (ARDS, death, other) were recorded up to 30 days after procedure. Oxygen saturation, supplemental oxygen use and temperature were recorded daily at baseline and after thoracoscopic pleurodesis (Graded talc, 2 g).

Results

During the 30-day observation period after talc poudrage, no ARDS (CI95% 0.0% – 0.9%), intensive care unit admission or death were recorded. Seven patients presented minor complications (1.7% CI95% 0.7 – 3.4). After pleurodesis, mean body temperature rose by 0.41 °C (CI95% 0.33-0.48; p<0.001) at day 1 and return to baseline value at day 5. Pleural drains were removed after day 4 in 80% of patients.

Conclusion:

Serious adverse events, including ARDS or death did not occur in this large, multicentric cohort. Thoracoscopic talc poudrage using larger particle talc to prevent recurrence of primary spontaneous pneumothorax can be considered safe.
INTRODUCTION

Talc powder is the most inexpensive and efficient agent for pleurodesis as shown in human[1-3] and animal studies[4]. We recently showed in a prospective cohort study that thoracoscopic large-particle talc poudrage is safe in the treatment of malignant pleural effusions[5]. Apart from treating malignant pleural effusions such graded talc has been extensively and safely used in Europe for more than 70 years for pleurodesis in recurrent spontaneous pneumothorax and has been shown to be well tolerated without long term sequellae[6-9].

However, there is continued concern about the safety of talc pleurodesis for this indication following American reports of ARDS after talc application [10-13]. However, the incidence of ARDS after talc poudrage in PSP is low. In a review of the literature from 1958 to 2001, Sahn found reports of 1 case of respiratory failure after talc pleurodesis in 659 patients (0.15%) [14]. Possible explanations for the occurrence of adult respiratory distress syndrome might be the dose of talc used [15, 16], the size of talc particles [17] as preparations vary markedly from one supplier to the other [18] or the form of talc administered (slurry talc versus poudrage [10, 19]. These possible causes were postulated after occurrence of ARDS in patients with malignant pleural effusion and not pneumothorax.

The aim of this study was to assess the safety of large-particle talc applied in a standardised dose, as poudrage under thoracoscopy in patients with recurrent primary spontaneous pneumothorax.

METHODS

Patients

Patients were prospectively enrolled between 2002 and 2008. Inclusion criteria were recurrent spontaneous pneumothorax for which the physician considered talc pleurodesis indicated.
Patients with active pulmonary infection, unstable respiratory condition, bleeding disorders, bilateral pneumothorax or parenchymal lung disease, prior ipsilateral thoracic surgery or pleurodesis or pregnancy were excluded. The study was approved by the Ethics committee of each participating hospitals. Informed consent was obtained according to local protocols.

**Thoracoscopic procedure**

Thoracoscopy was performed under general or local anesthesia by experienced pulmonologists according to current practice in Europe[20]. One or two entry ports were used to insert the videothoracoscope and the pneumatic atomiser. Two grams of graded talc (Steritalc®, Novatech, La Ciotat, France) were gently insufflated under visual control all over the pleural surface [21]. Graded talc is characterized by the particle size which has to be larger than 10 micrometers and should contain only a small percentage of smaller particles. Thus, particles have little or no capability to cross pleural stomata which have a diameter of 6 micrometers. Median particle size of Steritalc is 31.5 micrometers which is larger than talc manufactured in USA[22].

At the end of the procedure a standard chest tube (20 to 28 French) was inserted for drainage of air and fluid. Anti-emetics and analgesics were administered according to the patients needs.

During the 5 following days, vital signs, temperature, use of supplemental oxygen and all medical and surgical complications were recorded. If necessary, additional chest X-rays were ordered. Drain removal day was left at discretion of performing physicians.

**Statistical analyses**

Our primary endpoint was ARDS during the first 30 days after the procedure. Based on published literature, we estimated the risk of ARDS below 1%. We used exact confidence
interval according to Clopper and Pearson[23]. After an interim analysis, patients’ inclusion was stopped after 418 cases, because no ARDS case was identified. Comparisons of proportion of patients on supplemental oxygen and oxygen flow were done using multilevel logistic and linear regression accounting for repeated measure.
All analyses were performed with Stata 10 (4905 Lakeway Drive, College Station, 77845 Texas).

**RESULTS**

**Table 1** shows the characteristics of included patients (n=418). Most of them were young (age 30.5 [SD 12.7]) males (72.7%). For 61.1% of the thoracoscopies, two entry ports were used. Among the 9 centres in Europe and South Africa participating in the study, 2 centres used exclusively 2 ports (Roma, Brussels).

During the study period, no patients experienced ARDS or ICU admission (CI95% 0.0% – 0.9%). (**Table 2**)

Supplemental oxygen was provided to most patients on day 0. By day 5, only 6 (0.01%) patients were still on oxygen (**Figure 1**). Mean oxygen flow decreased from 1.9 L/min on day 0 to 0.5 L/min on day 5.

We observed a significant rise in temperature from baseline through day 4 and a return to baseline value on day 5. The mean temperature rose maximally by 0.41 Celsius (CI95% 0.33-0.49) on day 1 and by 0.37 °C (CI95% 0.29 – 0.44) on day 2 compared to baseline. On day 1, the temperature exceeded 37.9 Celsius in 83 patients (21.2%). Box plots with extreme values shows the temperature changes in **figure 2**.

We recorded 7 (1.7% CI95% 0.3% – 3.4%) non-ARDS complications (**Table 2**). Most frequent complication was pulmonary infections requiring antibiotics (n=3). We observed 4
cases of pleurodesis failure of pleurodesis requiring surgical procedure. Those four patients (<1%) were aged 20 to 84 and had persistent leaks for more than 2 days. In one case bulla had to be surgically resected.

Drains were removed on day 4 or before following thoracoscopy in 80% of patients. In 2 patients, drainage was removed on days 7 and 8 respectively. (Figure 3).

Table 1 Patients characteristics

<table>
<thead>
<tr>
<th></th>
<th>N</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>418</td>
<td></td>
</tr>
<tr>
<td>Males</td>
<td>304</td>
<td>72.7</td>
</tr>
<tr>
<td>Females</td>
<td>114</td>
<td>27.3</td>
</tr>
<tr>
<td>Age, mean (SD), Range</td>
<td>30.5 (12.7) [15-84]</td>
<td></td>
</tr>
<tr>
<td>Centres</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nijmegen (NL)</td>
<td>65</td>
<td>15.5</td>
</tr>
<tr>
<td>Montana (CH)</td>
<td>26</td>
<td>6.2</td>
</tr>
<tr>
<td>Marseille (F)</td>
<td>8</td>
<td>1.9</td>
</tr>
<tr>
<td>Lille (F)</td>
<td>46</td>
<td>11.0</td>
</tr>
<tr>
<td>Alexandroupolis (GR)</td>
<td>1</td>
<td>0.2</td>
</tr>
<tr>
<td>Brussels (B)</td>
<td>14</td>
<td>3.4</td>
</tr>
<tr>
<td>CapeTown (SA)</td>
<td>3</td>
<td>0.7</td>
</tr>
<tr>
<td>Turnhout (B)</td>
<td>34</td>
<td>8.1</td>
</tr>
<tr>
<td>Roma (I)</td>
<td>221</td>
<td>52.9</td>
</tr>
</tbody>
</table>

Table 2 Post-pleurodesis complications at 30 days

<table>
<thead>
<tr>
<th></th>
<th>N</th>
<th>%</th>
<th>CI95%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute Respiratory Distress Syndrome</td>
<td>0</td>
<td>-</td>
<td>0.0% – 0.9%*</td>
</tr>
<tr>
<td>Intensive Care Admission</td>
<td>0</td>
<td>-</td>
<td>0.0% – 0.9%*</td>
</tr>
<tr>
<td>Others †</td>
<td>7</td>
<td>1.7%</td>
<td>0.7% – 3.4%</td>
</tr>
</tbody>
</table>

*One sided confidence interval † Pulmonary infections requiring antibiotics (n=3), Urinary retention on opiates (n=1), Contralateral pneumothorax on day 2 (n=1), persisting pneumothorax (n=1), Sub-cutaneous emphysema (n=1).

DISCUSSION

The current study confirms the safety of thoracoscopic pleurodesis with graded talc for the treatment of recurrent primary spontaneous pneumothorax. No ARDS, intensive care unit
admission or death were observed in our series of 418 patients. The most frequent adverse event was temperature rise, which was maximal on day 1. This result is in line with previous study which documented the systemic inflammatory response induced by talc[24].
Supplemental oxygen was provided for a short period of time after talc pleurodesis. This suggests that talc-induced systemic inflammation is limited in severity and duration.
Complications were pulmonary infections in less than 1 percent of procedures.
The absence of ARDS found in our prospective study supports the safety of graded talc use for pleurodesis in recurrent primary spontaneous pneumothorax, as has been found in large retrospective studies before [3, 20, 25].
Talc pleurodesis has been shown to be efficacious and safe with success rate of 95% in PSP in large series [6-9, 25-27]. However, concerns about the safety of talc for pleurodesis were based on a small number of retrospective anecdotal reports of acute respiratory failure in patients with malignant pleural effusion [11-13]. In these reports non graded talc was used, which has been described to cross the visceral pleura and then cause systemic inflammation, ARDS and even some deaths[12, 19]. Moreover a very recent study from North America using higher dosage of talc (6 g) of unknown calibration raised concern about respiratory deterioration after thoracoscopic talc poudrage even if the used talc was the only one approved by the Food and Drug Administration[13]. Recent studies, using graded talc with large particle size, failed to observe ARDS cases [3, 7, 28]. Also, systemic side effects of talc appear to be related in humans to overdoses of talc or uncalibrated talc with small particles [17].
Besides, acute respiratory failure after re-expansion of the lung in the treatment of pneumothorax can occur due to re-expansion oedema without pleurodesis, as has been reported again recently[29].
Lack of power of our study to demonstrate an increased risk of ARDS might be discussed. However, our series is large enough to estimate this risk below 1%, which is clinically meaningful in regard of the risk of associated pneumothorax recurrence if left without pleurodesis.

In summary, our prospective study confirms on a large scale the short term safety of talc pleurodesis in the treatment of patients with recurrent spontaneous pneumothorax.

Figures (see attached files)

Figure 1 Supplemental post-pleurodesis oxygen use
Figure 2 Temperature change

Squares: median values. Circles: extreme values. P values compared to baseline values.
Figure 3 Drain removal day

Figure 3 Drain removal day

Data on drain removal were available for 264 patients. For 2 patients, drains were removed on day 7 and 8.

Contributors:
The study protocol was designed by JMT, CHM, MN, PA, PD, MF and JJ. All authors have contributed cases. JJ coordinated the study and collected the data. The spreadsheet for data collection was developed by JMT. POB did the statistical analysis, with external consultation. POB and JMT drafted the manuscript, which was contributed to by all authors. All authors have seen and approved the final version.

Research support:
We thank the Lancardis Foundation (CH-1920 Martigny, Switzerland) for its financial support to the study.

Conflict of interest:
Acknowledgements:

We are indebted to the physicians who contributed to the data collection and the Centre de Recherche Clinique of the University of Geneva for statistical advice (Delphine Courvoisier).

REFERENCES


